Adaptimmune Inc. (NASDAQ: ADAP) stock gained by 20.85% in the pre-market trading session. Adaptimmune is a clinical-stage pharmaceutical firm focusing on developing new cancer immunotherapy medicines for cancer patients. The SPEAR T-cell platform, developed by the company, allows T-cells to be engineered to target and eradicate cancer in a variety of solid tumors.
ADAP stock’ Current Development
Adaptimmune Therapeutics has established a strategic partnership and license agreement with Genentech which is a Roche Group company, to develop and market allogeneic cell treatments for a variety of cancer conditions.
Top 5 Cheap Stocks to Own Right Now
While finding safe stocks with the potential for monster gains isn't always easy, we've found a few that could pay out well. In fact, within our report, "Top 5 Cheap Stock to Own Right Now", we have identified five stocks we believe could appreciate the most even if you just have $1,000 to invest.
Sign up here to get your free report now. .
There are two parts to the collaboration:
- Allogeneic T-cell treatments for up to five common cancer targets are being developed.
- Personalized allogeneic T-cell treatments are being developed.
Adaptimmune will be in charge of developing clinical candidates for each component using its allogeneic platform developed from induced pluripotent stem cells to manufacture T-cells. Genentech will be in charge of the input TCRs, as well as clinical research and commercialization.
Adaptimmune will receive a $150 million upfront payment and subsequent installments of $150 million over the next five years unless the arrangement is terminated early. In addition, Adaptimmune could be eligible for payments totaling more than $3 billion in research, development, regulatory, and commercial milestones.
On Thursday, September 9, ADAP will give a live virtual update to explain its allogeneic platform and future development goals.
Adrian Rawcliffe, Adaptimmune’s Chief Executive Officer stated,
Given Genentech’s dedication to patients and science in the field of cancer immunology, they are honored to collaborate with them. Adaptimmune’s leadership position in developing allogeneic cell treatments is strengthened by this partnership, which builds on their extensive experience obtained from their autologous clinical trials. Their platform will be the foundation of a personalized allogeneic cell therapy vision in which every patient can receive a T-cell product for their cancer as a result of their collaboration, which is a huge step toward their aim of making cell treatments both curative and mainstream.